Board of Governors of the Federal Reserve System, March 12, 1982.

Theodore E. Downing, Jr.,

Assistant Secretary of the Board.

[FR Doc. 82-7418 Filed 3-18-82; 8:45 am]

BILLING CODE 6210-01-M

Peoples Bancorp, Inc.; Formation of Bank Holding Company

Peoples Bancorp, Inc., Burlington, Kansas, has applied for the Board's approval under section 3(a)(1) of the Bank Holding Company Act (12 U.S.C. 1842(a)(1)) to become a bank holding company by acquiring 100 percent of the voting shares of First National Bank of Elk City, Elk City, Kansas. The factors that are considered in acting on the application are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

The application may be inspected at the offices of the Board of Governors or at the Federal Reserve Bank of Kansas City. Any person wishing to comment on the application should submit views in writing to the Reserve Bank, to be received not later than April 11, 1982. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Board of Governors of the Federal Reserve System, March 12, 1982.

Theodore E. Downing, Jr.,

Assistant Secretary of the Board.

[FR Doc. 82-7405 Filed 3-18-82; 8:45 am]

BILLING CODE 6210-01-M

Rock Creek Bancshares Inc.; Acquisition of Bank

Rock Creek Bancshares Inc., Burlington, Kansas, has applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) to acquire 100 percent of the preferred nonvoting shares of Peoples Bancorp, Inc., Burlington, Kansas. The factors that are considered in acting on the application are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

The application may be inspected at the offices of the Board of Governors or at the Federal Reserve Bank of Kansas City. Any person wishing to comment on the application should submit views in writing to the Reserve Bank, to be received not later than April 11, 1982. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Board of Governors of the Federal Reserve System, March 12, 1982.

Theodore E. Downing, Jr.,

Assistant Secretary of the Board.

[FR Doc. 82-7419 Filed 3-18-82; 8:45 am]

BILLING CODE 6210-01-M

Santa Barbara Bancorp; Formation of Bank Holding Company

Santa Barbara Bancorp, Santa Barbara, California, has applied for the Board's approval under section 3(a)(1) of the Bank Holding Company Act (12 U.S.C. 1842(a)(1)) to become a bank holding company by acquiring 100 percent of the voting shares of Santa Barbara Bank and Trust, Santa Barbara, California. The factors that are considered in acting on the application are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

The application may be inspected at the offices of the Board of Governors or at the Federal Reserve Bank of San Francisco. Any person wishing to comment on the application should submit views in writing to the Reserve Bank, to be received not later than April 11, 1982. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Board of Governors of the Federal Reserve System, March 12, 1982.

Theodore E. Downing, Jr.,

Assistant Secretary of the Board.

[FR Doc. 82-7404 Filed 3-18-82; 8:45 am]

BILLING CODE 6210-01-M

United Hamblen, Inc.; Formation of Bank Holding Company

United Hamblen, Inc., Morristown, Tennessee, has applied for the Board's approval under section 3(a)(1) of the Bank Holding Company Act (12 U.S.C. 1842(a)(1)) to become a bank holding company by acquiring 80 percent or more of the voting shares of Bank of Commerce, Morristown, Tennessee. The factors that are considered in acting on the application are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

The application may be inspected at the offices of the Board of Governors or at the Federal Reserve Bank of Atlanta. Any person wishing to comment on the application should submit views in writing to the Reserve Bank, to be received not later than April 9, 1982. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Board of Governors of the Federal Reserve System, March 12, 1982.

Theodore E. Downing, Jr.,

Assistant Secretary of the Board.

[FR Doc. 82-7420 Filed 3-18-82; 8:45 am]

BILLING CODE 6210-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 82F-0046]

Air Products & Chemicals, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Air Products & Chemicals, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of ethylene oxide adduct of 2,4,7,9-tetramethyl-5-decyn-4,7-diol as an adjuvant in can coating formulations.

FOR FURTHER INFORMATION CONTACT: Julius Smith, Bureau of Foods (HFF-334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP OB-3515) has been filed by Air Products & Chemicals, Inc., Box 538, Allentown, PA 18105, proposing that § 175.300(b)(3)(xxix) (21 CFR 175.300(b)(3)(xxix)) be amended to provide for the safe use of ethylene oxide adduct of 2,4,7,9-tetramethyl-5-decyn-4,7-diol as an adjuvant in can coating formulations.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21

CFR 25.40(c) (proposed December 11, 1979; 44 FR 71742).

Dated: March 8, 1982.

Sanford A. Miller,

Director, Bureau of Foods.

[FR Doc. 82-7120 Filed 3-18-82; 8:45 am]

BILLING CODE 4160-01-M

Consumer Participation: Open Meetings

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the following consumer exchange meetings: Chicago District Office, Chaired by William R. Clark, District Director.

DATE: Wednesday, March 24, 1982, 7 p.m. to 9 p.m.

ADDRESS: School Cafeteria, Hawthorn School District #73, 201 Hawthorn Parkway, Vernon Hills, IL 60061.

FOR FURTHER INFORMATION CONTACT: Marie Ekvall, consumer Affairs Officer, Food and Drug Administration, 433 W. Van Buren St., Rm, 1222, Chicago, IL 60607, 312-353-7126.

San Francisco District Office, Chaired by William C. Hill, District Director.

DATE: WEDNESDAY, MARCH 24, 1982, 1 P.M.

ADDRESS: Food and Drug Administration, San Francisco District Office, 50 United Nation Plaza, Rm. 546, San Francisco, CA 94102.

FOR FURTHER INFORMATION CONTACT: Karen K. Erdman, Consumer Affairs Officer, Food and Drug Administration, 50 United Nations Plaza, San Francisco, CA 94102, 415-556-2062.

Boston District Office, Chaired by Frederick R. Carlson, District Director.

DATE: Wednesday, March 24, 1982, 9:30 a.m. to 12 m.

ADDRESS: Church Street Center of the University of Vermont, Burlington, Vermont.

FOR FUTHER INFORMATION CONTACT. Yolan L. Harsayi, Consumer Affairs Officer, Food and Drug Administration, 585 Commercial St., Boston, MA 02109, 617-223-5857.

Minneapolis District Office, Chaired by Henry P. Roberts, District Director.

DATE: Tuesday, March 30, 1982, 1 p.m.

ADDREESS: Northside Senior Citizen Center, 1711 W. Broadway, Minneapolis, MN.

FOR FURTHER INFORMATION CONTACT: Blanche L. Erkel, Consumer Affairs Officer, Food and Drug Administration, 240 Hennepin Ave., Minneapolis, MN 55401, 612-725-2121.

SUPPLEMENTARY INFORMATION: The purpose of these meetings is to encourage dialogue between consumers and FDA officials, to identify and set priorities for current and future health concerns, to enhance understanding and exchange information between local consumers and FDA's District Offices, and to contribute to the agency's policymaking decisions on vital issues.

Dated: March 11, 1982.

William F. Randolph,

Acting Associate Commissioner for Regulatory Affairs.

[FR Doc. 82-7117 Filed 3-18-82; 12:39 pm]

BILLING CODE 4160-01-M

[Docket No. 82F-0041]

E. I. du Pont de Nemours & Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that E. I. du Pont de Nemours and Co., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of polyamide-imide resins as components of articles intended for repeated use in contact with food.

FOR FURTHER INFORMATION CONTACT: Rudolph Harris, Bureau of Foods (HFF-334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 6B3141) has been filed by E. I. du Pont de Nemours and Co., Wilmington, Delaware 19898, proposing that § 177.2450 *Polyamide-imide resins* (21 CFR 177.2450) be amended to provide for the safe use of polyamide-imide resin produced by the condensation reaction of benzoyl chloride-3,4-dicarboxylic anhydride and 4,4'-diphenyl-methane diamine as components of articles intended for repeated use in contact with food.

The agency has carefully considered the potential environmental effects of this action and has concluded that the action will not have a significant impact on the human environment and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

Dated: March 8, 1982.

Sanford A. Miller,

Director, Bureau of Foods.

[FR Doc. 82-7118 Filed 3-18-82; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 82F-0026]

Toyo Seikan Kaisha, Ltd.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Toyo Seikan Kaisha, Ltd., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of a certain aliphatic polyurethane laminating adhesive for fabricating retortable pouches and related high-temperature laminates.

FOR FURTHER INFORMATION CONTACT: Terry C. Troxell, Bureau of Foods (HFF-334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 2B3615) has been filed by Toyo Seikan Kaisha, Ltd., 3-1 Uchisaiwaicho 1-Chome, Chiyoda-ku, Tokyo 100, Japan, proposing that the food additive regulations be amended to provide for the safe use of a 2-component aliphatic polyurethane laminating adhesive based on 3-isocyanatomethyl-3,5,5-trimethylcyclohexyl isocyanate, and certain polybasic acids and polyhydric alcohols listed in § 175.300(b)(3)(vii) (21 CFR 175.300(b)(3)(vii)) for fabricating retortable pouches and other high-temperature laminates identified in § 177.1390(c) (21 CFR 177.1390(c)).

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c) (proposed December 11, 1979; 44 FR 71742).

Dated: March 8, 1982.

Sanford A. Miller,

Director, Bureau of Foods.

[FR Doc. 82-7119 Filed 3-18-82; 8:45 am]

BILLING CODE 4160-01-M

Gastrointestinal Drugs Advisory Committee; Renewal

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: Under the Federal Advisory Committee Act of October 6, 1972 (Pub. L. 92-463, 86 Stat. 770-776 (5 U.S.C. App. I)), the Food and Drug Administration announces the renewal of the Gastrointestinal Drugs Advisory Committee by the Secretary, Department of Health and Human Services.

DATE: Authority for this committee will expire on March 3, 1984, unless the Secretary formally determines that renewal is in the public interest.

FOR FURTHER INFORMATION CONTACT: Richard L. Schmidt, Committee Management Office (HFA-306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-2765.

Dated: March 12, 1982.

William F. Randolph,

Acting Associate Commissioner for Regulatory Affairs.

[FR Doc. 82-7269 Filed 3-18-82; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 82F-0044]

Centre Pharmaceutique European; Withdrawal of Petition for Food Additive

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal without prejudice of a petition proposing the safe use of 2-phenylindole as an antioxidant and/or stabilizer in the manufacture of vinyl chloride copolymers intended for food contact applications.

FOR FURTHER INFORMATION CONTACT: Garnett R. Higginbotham, Bureau of Foods (HFF-334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b), 72 Stat. 1786 (21 U.S.C. 348(b))), the following notice is issued.

In accordance with § 171.7 *Withdrawal of petition without prejudice* (21 CFR 171.7), Division Sapchim, Centre Pharmaceutique European (formerly Sapchim-Fournier-Cimag), Paris, France, has withdrawn its petition (FAP 5B3031), notice of which was published in the **Federal Register** of October 24, 1974 (39 FR 37795) proposing that § 121.2566 (now § 178.2010, 21 CFR 178.2010) of the food additive regulations be amended to provide for the safe use of 2-phenylindole as an antioxidant and/or stabilizer in the manufacture of vinyl chloride copolymers intended for food-contact applications.

Dated: March 12, 1982.

Sanford A. Miller,

Director, Bureau of Foods.

[FR Doc. 82-7422 Filed 3-18-82; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 82F-0048]

Ciba-Geigy Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ciba-Geigy Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of triphenyl phosphorothionate as an antiwear/extreme pressure additive in lubricants with incidental food contact.

FOR FURTHER INFORMATION CONTACT: Andrew D. Laumbach, Bureau of Foods (HFF-334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 2B3621) has been filed by Ciba-Geigy Corp., Plastics and Additives Division, Hawthorne, NY 10532, proposing that § 178.3570 *Lubricants with incidental food contact* (21 CFR 178.3570) be amended to provide for the safe use of triphenyl phosphorothionate as an antiwear/extreme pressure additive in lubricants with incidential food contact.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c) (proposed December 11, 1979; 44 FR 71742).

Dated: March 12, 1982.

Sanford A. Miller,

Director, Bureau of Foods.

[FR Doc. 82-7424 Filed 3-18-82; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 82D-0053]

Guidelines for Evaluating Electromagnetic Exposure Risk for Trials of Clinical NMR Systems; Availability

AGENCY: Food and Drug Administration.

ACTION: Notice of availability.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of guidelines entitled, "Guidelines for Evaluating Electromagnetic Exposure Risk for Trials of Clinical NMR Systems," developed by the Bureau of Radiological Health. The guidelines provide guidance to sponsors and to Institutional Review Boards (IRB's) for determining whether a clinical study involving a nuclear magnetic resonance (NMR) device represents a "significant risk" under the investigational device exemption (IDE) regulations.

ADDRESSES: Written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857. A single copy of the guidelines may be obtained from the Bureau of Radiological Health (HFX-460), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. In addition, a copy of the guidelines is on file for public display at the Dockets Management Branch.

FOR FURTHER INFORMATION CONTACT: Robert A. Phillips, Bureau of Radiological Health (HFX-460), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-3426.

SUPPLEMENTARY INFORMATION: Under 21 CFR Part 812 (the IDE regulations), the sponsor of a medical device and ultimately an IRB have the initial responsibility to determine whether any clinical investigation of the device presents a "significant risk;" that is, whether it represents a "potential for serious risk to the health, safety, or welfare of a subject." A finding of "significant risk" does not mean that a device is too hazardous for clinical studies but that an IDE application must be submitted to FDA for approval of the investigation. Through the FDA review process, the safety aspects of the study will be independently evaluated. Generally, if any reviewing IRB finds